IRB Study Number 23-833
Status Recruiting
Phase Phase 2
Location Cleveland Clinic Main Campus
Institute Endocrinology and Metabolism Institute
Description
The purpose of this research trial is to investigate the effects of LY3437943 (drug) compared with placebo on renal function, in participants who are overweight or obese with Chronic Kidney disease with or without type 2 diabetes. This is a phase 2b, double-blinded study.
Screening Period: up to 35 days
Treatment Period: 24 weeks
Follow-Up Period: 4 weeks after end of treatment period
Inclusion Criteria
-18 or older
-BMI of at least 27
-Diagnosed CKD
Exclusion Criteria
-Self-reported changed in body weight greater that 5kg (11lbs) in 90 days before screening
-Prior or planned surgical treatment for obesity
-Type 1 Diabetes
-Have taken any medication within 90 days before screening intended to promote body weight reduction
-Known allergies or intolerance to GLP-1R agonists, GIP/GLP-1R agonist, or LY3437943
-Known allergies, intolerance, or other contraindication to iohexal injection, such as iodine or contrast allergy
-Any contraindication for MRI
